Coelho J, Ferreira A, Abreu AC, et al. - Researchers conducted this single-center retrospective observational case series to assess the prevalence and visual outcomes of macular Bruch membrane (BM) defects in patients treated with anti-vascular endothelial growth factors (VEGF) for choroidal neovascularization secondary to pathological myopia (mCNV). Participants in the study were 62 patients (68 eyes) with mCNV treated with one anti-VEGF injection followed by a pro re nata (1 + PRN) regimen. Macular Bruch membrane defects are common in mCNV, and they affect visual acuity and prognosis significantly. After anti-VEGF therapy, eyes with macular BM defects have a poorer response and worse visual outcomes.